Slideshow
Number Needed to Harm: Opportunistic Infections of IL Inhibitors in Rheumatology
Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.
Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.RELATED: News report:Â "Interleukin Inhibitors May Raise Infection, Cancer Risks" Commentary: "Infections and Cancer More Common in Rheumatology Than Previously Thought"
